Home LiteratureArticle Details
PMID: 10933680 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Journal of virology ·Vol. 74 ·No. 17 ·2000-09-00 ·Pages 7745-54

Murphy CG, Lucas WT, Means RE, Czajak S, Hale CL, Lifson JD, Kaur A, Johnson RP, Knipe DM, Desrosiers RC

Abstract

An effective vaccine for AIDS may require development of novel vectors capable of eliciting long-lasting immune responses. Here we report the development and use of replication-competent and replication-defective strains of recombinant herpes simplex virus (HSV) that express envelope and Nef antigens of simian immunodeficiency virus (SIV). The HSV recombinants induced antienvelope antibody responses that persisted at relatively stable levels for months after the last administration. Two of seven rhesus monkeys vaccinated with recombinant HSV were solidly protected, and another showed a sustained reduction in viral load following rectal challenge with pathogenic SIVmac239 at 22 weeks following the last vaccine administration. HSV vectors thus show great promise for being able to elicit persistent immune responses and to provide durable protection against AIDS.

MeSH Terms
Animals Antibodies, Viral/biosynthesis Injections, Intravenous Macaca mulatta SAIDS Vaccines/biosynthesis,genetics,immunology Simian Acquired Immunodeficiency Syndrome/immunology,prevention & control Simian Immunodeficiency Virus/immunology Simplexvirus/genetics,immunology,metabolism Vaccines, Attenuated/biosynthesis,genetics,immunology Vaccines, Synthetic/biosynthesis,genetics,immunology Viral Envelope Proteins/immunology,metabolism Viral Load Virus Replication
Chemicals
Antibodies, Viral SAIDS Vaccines Vaccines, Attenuated Vaccines, Synthetic Viral Envelope Proteins
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Murphy C G
Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115-5716, USA.
Lucas W T
Means R E
Czajak S
Hale C L
Lifson J D
Kaur A
Johnson R P
Knipe D M
Desrosiers R C
References (48)
48 references, click to expand
  1. A role for carbohydrates in immune evasion in AIDS.
    Nat Med. 1998 Jun;4(6):679-84 PMID: 9623976
  2. Titration and characterization of two rhesus-derived SIVmac challenge stocks.
    AIDS Res Hum Retroviruses. 1994 Feb;10(2):213-20 PMID: 8198874
  3. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia.
    Immunity. 1998 Jun;8(6):683-91 PMID: 9655482
  4. Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant.
    J Virol. 1998 Aug;72(8):6710-5 PMID: 9658118
  5. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.
    J Virol. 1998 Aug;72(8):6950-5 PMID: 9658152
  6. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.
    J Virol. 1998 Oct;72(10):8264-72 PMID: 9733870
  7. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.
    J Virol. 1999 Jun;73(6):4952-61 PMID: 10233957
  8. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.
    Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6994-8 PMID: 10359827
  9. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
    Nat Med. 1999 Jun;5(6):643-50 PMID: 10371502
  10. Strategies used by human immunodeficiency virus that allow persistent viral replication.
    Nat Med. 1999 Jul;5(7):723-5 PMID: 10395309
  11. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.
    J Virol. 1999 Oct;73(10):8201-15 PMID: 10482571
  12. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.
    J Virol. 1999 Oct;73(10):8356-63 PMID: 10482586
  13. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
    J Virol. 2000 Feb;74(4):1704-11 PMID: 10644340
  14. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.
    J Virol. 2000 Mar;74(6):2584-93 PMID: 10684272
  15. Depressed specific cell-mediated immunity to Herpes simplex virus type 1 in patients with recurrent herpes labialis.
    Infect Immun. 1975 Jul;12(1):76-80 PMID: 166930
  16. A new method for the isolation of herpes simplex virus type 2 DNA.
    Virology. 1976 Oct 1;74(1):256-8 PMID: 185791
  17. Molecular genetics of herpes simplex virus. III. Fine mapping of a genetic locus determining resistance to phosphonoacetate by two methods of marker transfer.
    J Virol. 1979 Feb;29(2):698-704 PMID: 219255
  18. Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus.
    J Virol. 1982 Jul;43(1):314-24 PMID: 6287005
  19. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus.
    J Gen Virol. 1987 Dec;68 ( Pt 12):3183-9 PMID: 2826656
  20. Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein.
    J Virol. 1989 Dec;63(12):5258-67 PMID: 2555553
  21. Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27.
    J Virol. 1990 Apr;64(4):1704-15 PMID: 2157053
  22. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus).
    J Infect Dis. 1990 Aug;162(2):313-21 PMID: 2165104
  23. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    J Virol. 1994 Oct;68(10):6578-88 PMID: 7521918
  24. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1.
    J Virol. 1995 Aug;69(8):4898-905 PMID: 7609058
  25. Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1.
    J Neuroimmunol. 1995 Aug;61(1):7-16 PMID: 7560014
  26. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection.
    J Virol. 1996 Jan;70(1):264-71 PMID: 8523535
  27. Simian immunodeficiency virus DNA vaccine trial in macaques.
    J Virol. 1996 Jun;70(6):3978-91 PMID: 8648735
  28. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1.
    Virology. 1996 Jun 15;220(2):402-13 PMID: 8661391
  29. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.
    AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):985-92 PMID: 8827214
  30. Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1.
    J Immunol. 1996 Oct 15;157(8):3542-9 PMID: 8871654
  31. Induction of AIDS by simian immunodeficiency virus lacking NF-kappaB and SP1 binding elements.
    J Virol. 1997 Mar;71(3):1880-7 PMID: 9032318
  32. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.
    J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8 PMID: 9266987
  33. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.
    J Virol. 1997 Oct;71(10):7711-8 PMID: 9311855
  34. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.
    J Virol. 1997 Oct;71(10):7895-902 PMID: 9311879
  35. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.
    AIDS Res Hum Retroviruses. 1990 Nov;6(11):1221-31 PMID: 2078405
  36. Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens.
    J Virol. 1992 Mar;66(3):1622-34 PMID: 1310769
  37. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.
    J Virol. 1992 Dec;66(12):7067-72 PMID: 1331509
  38. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.
    J Virol. 1993 Jan;67(1):577-83 PMID: 8416384
  39. Lentivirus envelope sequences and proviral genomes are stabilized in Escherichia coli when cloned in low-copy-number plasmid vectors.
    Gene. 1993 Feb 14;124(1):93-8 PMID: 8382658
  40. A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus.
    J Virol. 1997 Dec;71(12):9764-9 PMID: 9371642
  41. Identification of highly attenuated mutants of simian immunodeficiency virus.
    J Virol. 1998 Feb;72(2):1431-7 PMID: 9445045
  42. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction.
    AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):183-9 PMID: 9462929
  43. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus.
    J Gen Virol. 1998 Mar;79 ( Pt 3):423-32 PMID: 9519819
  44. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
    J Virol. 1998 May;72(5):4170-82 PMID: 9557706
  45. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs.
    J Infect Dis. 1998 May;177(5):1143-54 PMID: 9592996
  46. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
    J Virol. 1994 Feb;68(2):689-96 PMID: 8289372
  47. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    J Virol. 1994 Feb;68(2):927-32 PMID: 8289395
  48. Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein.
    J Virol. 1998 Jul;72(7):5399-407 PMID: 9620994
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/jvi.74.17.7745-7754.2000
Published
2000-09-00
Pages
7745-54
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC112303
Subset
IM
Grants
NIAID NIH HHS · AI46006 · United States
NCRR NIH HHS · RR00168 · United States
NCRR NIH HHS · P51 RR000168 · United States
NCRR NIH HHS · K26 RR000168 · United States
NIAID NIH HHS · AI38131 · United States
NIAID NIH HHS · P01 AI046006 · United States
External Links
PubMed source DOI: 10.1128/jvi.74.17.7745-7754.2000 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2